Open AccessThis article is
- freely available
siRNA Genome Screening Approaches to Therapeutic Drug Repositioning
Department of Infectious Diseases, University of Georgia, Animal Health Research Center, 111 Carlton Street, Athens GA 30602, USA
* Author to whom correspondence should be addressed.
Received: 20 December 2012; in revised form: 10 January 2013 / Accepted: 22 January 2013 / Published: 28 January 2013
Abstract: Bridging high-throughput screening (HTS) with RNA interference (RNAi) has allowed for rapid discovery of the molecular basis of many diseases, and identification of potential pathways for developing safe and effective treatments. These features have identified new host gene targets for existing drugs paving the pathway for therapeutic drug repositioning. Using RNAi to discover and help validate new drug targets has also provided a means to filter and prioritize promising therapeutics. This review summarizes these approaches across a spectrum of methods and targets in the host response to pathogens. Particular attention is given to the utility of drug repurposing utilizing the promiscuous nature of some drugs that affect multiple molecules or pathways, and how these biological pathways can be targeted to regulate disease outcome.
Keywords: RNAi; siRNA; miRNA; genome; antiviral; HTS; therapeutic; pathway; virus; bacteria; pathogen; reposition; repurpose; host genes
Citations to this Article
Cite This Article
MDPI and ACS Style
Perwitasari, O.; Bakre, A.; Tompkins, S.M.; Tripp, R.A. siRNA Genome Screening Approaches to Therapeutic Drug Repositioning. Pharmaceuticals 2013, 6, 124-160.
Perwitasari O, Bakre A, Tompkins SM, Tripp RA. siRNA Genome Screening Approaches to Therapeutic Drug Repositioning. Pharmaceuticals. 2013; 6(2):124-160.
Perwitasari, Olivia; Bakre, Abhijeet; Tompkins, S. M.; Tripp, Ralph A. 2013. "siRNA Genome Screening Approaches to Therapeutic Drug Repositioning." Pharmaceuticals 6, no. 2: 124-160.